NUVB — Nuvation Bio Inc.

Summary of Nuvation Bio Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $83.2 million, including $18.5 million from Iptrozy net U.S. product revenue, marking an 18% increase from the previous quarter.
• New Patient Starts: Approximately 200 new patients treated with Iptrozy for the third consecutive quarter, with over 600 total since launch.
• Revenue Growth: Driven by an increasing proportion of first-line patients, which rose from 30% to over 50% of new starts.
• Operating Expenses: Totaled $73.5 million, with R&D expenses at $35.0 million and SG&A expenses at $38.3 million.
• Cash Position: Ended the quarter with $533.7 million in cash, cash equivalents, and marketable securities.

2. Strategic Updates and Business Highlights

• Iptrozy Launch: Focused on building a successful commercial launch in ROS1-positive non-small cell lung cancer (NSCLC), emphasizing physician education and patient support.
• Clinical Data: Iptrozy demonstrated a median duration of response of 50 months in TKI-naive patients, reinforcing its efficacy and tolerability.
• NCCN Guidelines: Iptrozy was included in the latest NCCN CNS guidelines as a treatment option for patients with brain metastases, enhancing its market position.
• Safusitinib Development: Ongoing Phase 3 SIGMA study for IDH1-mutant glioma shows promise, with plans to expand into Japan following the acquisition of rights.

3. Forward Guidance and Outlook

• Revenue Expectations: Anticipate continued growth in Iptrozy revenue driven by the increasing number of first-line patients and the potential for revenue stacking as patient duration on therapy extends.
• Market Expansion: Plans to enhance patient identification through community education initiatives and partnerships to improve testing rates.
• Long-term Value: Confidence in Iptrozy's potential to capture a larger market share as awareness and testing improve.

4. Bad News, Challenges, or Points of Concern

• Patient Discontinuations: Discontinuations primarily among later-line patients due to disease progression, which may introduce variability in near-term revenue.
• Testing Rates: Lower testing rates in community settings compared to academic centers pose a challenge for patient identification and treatment initiation.
• Competitive Landscape: Emerging competitors are developing therapies that may impact treatment sequencing and market dynamics, though Iptrozy's efficacy remains a strong differentiator.

5. Notable Q&A Insights

• Adoption Dynamics: The increase in first-line patients is primarily from academic centers due to higher testing rates, with community centers lagging behind.
• Sales Force Initiatives: Nuvation Bio is actively addressing testing gaps in the community through educational initiatives and partnerships.
• Real-World Data: Early indications suggest that first-line patients are remaining on therapy longer than expected, aligning with clinical trial data.
• NCCN Guidelines Impact: The inclusion of Iptrozy in CNS guidelines is expected to positively influence treatment decisions among healthcare providers.
• Future Metrics: Analysts were advised to focus on the growth of first-line patients and revenue stacking rather than solely on new patient starts, as the latter may plateau due to the finite pool of late-line patients.

Overall, Nuvation Bio's Q1 2026 results reflect strong commercial momentum for Iptrozy, with a positive outlook driven by strategic initiatives and robust clinical data, despite challenges related to patient discontinuations and testing rates.